Follow on Google News News By Tag * Cancer Biotherapy * Radiopharmaceuticals * Metastatic Melanoma * Interleukin-2 * Mary Ann Liebert * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Can Personalized Tumor Vaccines Improve Interleukin-2 Treated Metastatic Melanoma?By: Mary Ann Liebert, Inc. publishers Can Personalized Tumor Vaccines Improve Survival of Patients with Interleukin- New Rochelle, NY—Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin- “High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines” (http://online.liebertpub.com/ “This is an important addition to the literature on IL2 treatment for metastatic melanoma demonstrating that personalized vaccine therapy contributed to an increased survival rate,” says Co-Editor-in- About the Journal Cancer Biotherapy and Radiopharmaceuticals, published 10 times a year in print and online, is under the editorial leadership of Editors Donald J. Buchsbaum, PhD and Robert K. Oldham, MD, Lower Keys Cancer Center, Key West, FL. Cancer Biotherapy and Radiopharmaceuticals is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways. Tables of content and a sample issue are available on the Cancer Biotherapy and Radiopharmaceuticals website (http://www.liebertpub.com/ About the Publisher Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Interferon & Cytokine Research; Human Gene Therapy, Human Gene Therapy Methods and Human Gene Therapy Clinical Development; and Stem Cells and Development. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com). Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101 End
Account Email Address Account Phone Number Disclaimer Report Abuse
|